How to buy GlaxoSmithKline shares in Ireland | $38.36

GlaxoSmithKline plc is a drug manufacturers-general business based in the US. GlaxoSmithKline shares (GSK) are listed on the NYSE and all prices are listed in US Dollars. GlaxoSmithKline employs 99,437 staff and has a market cap (total outstanding shares value) of USD$95.3 billion.

Sponsored For

Beginners Choice

DEGIRO

Sponsored For

Low-cost Trading

eToro

Sponsored For

Overall Broker

Plus500

How to buy shares in GlaxoSmithKline from Ireland

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for GlaxoSmithKline Find the stock by name or ticker symbol: GSK. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until GlaxoSmithKline reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$38.36, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of GlaxoSmithKline, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of GlaxoSmithKline. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Compare online brokers to trade stocks, ETFs and CFDs

Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89 % of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Sort by:

Name	Product	Number of Stocks	CFDs	Shares	Available Markets	Link
DEGIRO		Access to global markets	No	Yes	AU, AT, BE, CA, CH, CZ, DE, DK, ES, FR, FI, GR, HK, HU, IT, JP, NO, PT, PL, IE, SG, SE, TR, UK, US	Go to site More Info	Your capital is at risk.		loading Fetching your data...
eToro		2,000+	Yes	Yes	Worldwide with exception.	Go to site 71% of CFD accounts lose money More Info	CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.		loading Fetching your data...
Plus500		2,000+	Yes	Yes	US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK	Go to site 76.4% of CFD accounts lose money More Info	CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

GlaxoSmithKline share price

Is it a good time to buy GlaxoSmithKline stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is GlaxoSmithKline under- or over-valued?

Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

GlaxoSmithKline's P/E ratio

GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 39x. In other words, GlaxoSmithKline shares trade at around 39x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

GlaxoSmithKline's PEG ratio

GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 11.1767. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Shorting GlaxoSmithKline shares

There are currently 13.1 million GlaxoSmithKline shares held short by investors – that's known as GlaxoSmithKline's "short interest". This figure is 15.8% up from 11.3 million last month.

There are a few different ways that this level of interest in shorting GlaxoSmithKline shares can be evaluated.

GlaxoSmithKline's "short interest ratio" (SIR)

GlaxoSmithKline's "short interest ratio" (SIR) is the quantity of GlaxoSmithKline shares currently shorted divided by the average quantity of GlaxoSmithKline shares traded daily (recently around 4.2 million). GlaxoSmithKline's SIR currently stands at 3.1. In other words for every 100,000 GlaxoSmithKline shares traded daily on the market, roughly 3100 shares are currently held short.

However GlaxoSmithKline's short interest can also be evaluated against the total number of GlaxoSmithKline shares, or, against the total number of tradable GlaxoSmithKline shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GlaxoSmithKline's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 GlaxoSmithKline shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable GlaxoSmithKline shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against GlaxoSmithKline.

Frequently asked questions

• What percentage of GlaxoSmithKline is owned by insiders or institutions?

  Currently 0.011% of GlaxoSmithKline shares are held by insiders and 11.88% by institutions.

• How many people work for GlaxoSmithKline?

  Latest data suggests 99,437 work at GlaxoSmithKline.

• When does the fiscal year end for GlaxoSmithKline?

  GlaxoSmithKline's fiscal year ends in December.

• Where is GlaxoSmithKline based?

  GlaxoSmithKline's address is: 980 Great West Road, Brentford, United Kingdom, TW8 9GS

• What is GlaxoSmithKline's ISIN number?

  GlaxoSmithKline's international securities identification number is: US37733W1053

• What is GlaxoSmithKline's CUSIP number?

  GlaxoSmithKline's Committee on Uniform Securities Identification Procedures number is: 37733W105